EPHA3 and plasma cell myeloma: EPHA3 plays a crucial role in the angiogenesis of multiple myeloma (MM), and the specific targeting of EPHA3 using a monoclonal antibody has an impact on primary bone marrow endothelial cells (ECs) of MM patients.